With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical ...
Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...
Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.
Rezpegaldesleukin may be an effective therapeutic option for adults with moderate to severe AD as well as those with comorbid ...
LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm Hawaii 2026 (Jan. 25-29), showcasing a comprehensive body of evidence across ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an ...
A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new study says. Nemolizumab (Nemluvio) relieved itchiness within two days for three ...
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Kymera Therapeutics reported on Monday that, for the second time this year, it has ...
Because symptoms of atopic dermatitis (also known as eczema) like redness, scaly patches, and inflamed skin can be very visible, those with the condition sometimes bow out of social events and may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results